Tag: nivolumab

Nivolumab is a fully human IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor. By modulating immune checkpoints, nivolumab enhances the body’s antitumor immune response and has transformed the therapeutic landscape for various advanced malignancies. Mechanism of Action The PD-1 receptor, expressed on activated T cells, binds its ligands PD-L1 and PD-L2, typically upregulated…